Bristol Myers Squibb (BMS) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. New medical technologies, from innovative oncology and immunotherapies to mRNA and CRISPR gene editing offer unprecedented opportunities to improve the lives of Europeans.
BMS
Bristol Myers Squibb
Company · United States · EU Transparency Register 04437556781-76
4
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #380 by legislative files engaged, a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
€2.5M+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- EFPIA Oncology Platform
- EFPIA Cardiovascular Health Platform
- EFPIA Alzheimer's Platform
- DigitalEurope →
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) →
- Friends of Europe
- American Chamber of Commerce to the EU →
- American European Community Association (AECA)
- European Patients' Forum
- EURORDIS
- TRANSFORM Alliance
- and 1 more
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Bristol-Myers Squibb Company (BMS)
- Head office
- Princeton, New Jersey, United states
- EU office
- Ixelles
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Bristol in PolicySpeak: request access →
Work at Bristol Myers Squibb? so we know who speaks for it.
Their record over time
Bristol Myers Squibb filed 4 positions between 14 Dec 2020 and 9 Jun 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2020 · 1 filed2021 · 2 filed2026 · 1 filed
What they argued
BMS Response to the European Commission Call for Evidence: Biotech Act II Bristol Myers Squibb (BMS) welcomes the European Commission's Call for Evidence for the Biotech Act II and commends the initiative's ambition to build a more competitive, innovation-friendly regulatory environment for industrial biotechnology and biomanufacturing in the EU.
Bristol Myers Squibb (BMS) welcomes the opportunity to provide input in this public consultation for the revision of the Blood, Tissues & Cells Legislation. In this contribution we will focus on the Blood directive specifically. For our response to the Tissues & Cells Legislation, we refer to the contributions of EFPIA, ARM and EUCOPE.
As a global biopharmaceutical company focused on transforming the lives of patients through science, Bristol-Myers Squibb (BMS) strongly believes in a legislative framework conducive to medical innovation addressing unmet needs (UMN) and available to all patients who need it. However, we believe that the Commission’s options laid out in the inception impact assessment are unlikely to achieve the desired objectives.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Bristol Myers Squibb next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 79.
Is this your organization?
Everything on this page comes from Bristol Myers Squibb’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.